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Tumor-associated macrophages
(TAMs) are key components of the
tumor macroenvironment. Cancer-
and host cell-derived signals gener-
ally drive the functions of TAMs
towards an M2-like polarized, tumor-
propelling mode; however, when
appropriately re-educated. TAMs also
have the potential to elicit tumor
destructive reactions. Here, we
discuss recent advances regarding the
immunobiology of TAMs and high-
light open questions including the
mechanisms of their accumulation
(recruitment versus proliferation),
their diversity and how to best ther-
apeutically target these cells.
Introduction
It is estimated that about 25% of cancers
are linked to chronic inflammation
sustained by chronic infections (e.g.
inflammatory bowel disease, IBD) or
inflammatory conditions of diverse origin
(e.g. prostatitis) [1]. Moreover, inflam-
matory cells and mediators are also
present in the microenvironment of
virtually all tumors that are not epide-
miologically related to inflammation [1].
Two pathways link inflammation and
cancer. The first, the extrinsic pathway,
is driven by exogenous conditions which
cause non-resolving smouldering inflam-
matory responses; the second, the intrin-
sic pathway, is triggered by mutation of
either oncogenes or tumor suppressor
genes that activate the expression of
inflammation-related programmes [1].
Macrophages are a key component of
cancer-related inflammation (CRI) [1–4].
In many tumors, a correlation between
increased numbers and/or density of
macrophages and poor prognosis has
been observed [5–7]. The molecular
mechanisms underlying the cancer-
promoting activities of tumor-associated
macrophages (TAMs) include the promo-
tion of proliferation and survival of
malignant cells, the subversion of adap-
tive immune responses, and the promo-
tion of angiogenesis, stroma remodelling
and metastasis formation [1, 2]. More-
over, there is evidence strongly suggest-
ing that TAMs are critical determinants of
the tumor response to hormonal therapy
and chemotherapy [8–10].
Here, we will discuss recent advan-
ces that have shed new light onto the
immunobiology of TAMs and their
viability as therapeutic targets. In
particular, we will emphasize the open
questions and stumbling blocks to
diagnostic and therapeutic exploitation
building on previous reviews that
provide the framework for the present
contribution, which by virtue of being a
Viewpoint is restricted in length [1–4].
TAM accumulation
It has long been held that TAMs
originate from circulating monocytes
and that tumor-derived chemoattrac-
tants play a key role in monocyte
recruitment [11] (Fig. 1). Chemokines
(e.g. CCL2) have been known to be
associated with macrophage infiltration
in experimental and human tumors for
over 25 years (e.g. [12–16]). For
instance, gliomas are characterized by
the long recognized production of a
wide spectrum of chemokines, by the
expression of chemokine receptors and
by the correlations between chemokine
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production/receptor expression and
clinical outcome; the chemokine reper-
toire of gliomas includes CCL2, CXCL8,
CXCL12, CXCL10, CCL3L1, CX3CL1
(e.g. [17–19]).
It has been assumed that chemokine-
driven entry of monocytes accounts for
the maintenance of TAM levels in a
growing tumor; however, physiologically,
mouse microglia cells relevant to gliomas
are self-sustained and do not depend on
continuous replenishment from the circu-
lation [20]. Moreover, in a mouse model
of type II inflammation using nematode
infection, local IL-4-dependent macro-
phage proliferation is shown to be a key
determinant of the numbers of M2-polar-
ized macrophages in the lung [21]. In the
same vein, a recent paper in this Journal
by Taylor and colleagues demonstrates
that macrophage accumulation in the
inflamed peritoneum depends on
macrophage proliferation [22]. Early
studies also showed in situ proliferation
of TAMs (e.g. [23–25]) (Fig. 1). For
instance, in a murine sarcoma, a para-
crine circuit involving M-CSF produced
by tumor cells and high levels of c-fms
production by TAMs was identified as a
mechanism of macrophage proliferation
and survival in situ [25]; however, M-
CSF is a relatively poor CSF in humans
and therefore it remains unclear whether
proliferation is a major determinant
sustaining human macrophage numbers
in tissues [26, 27], although proliferation
[28] has been detected in human
monocytes. Furthermore, macrophage
mitosis has rarely been observed in
specimens from human tumors, with the
exception of Kaposi’s sarcoma [11].
Given the old and new findings
discussed here, the issue of in situ
macrophage proliferation as a mechan-
ism contributing to TAM levels needs to
be re-examined using the current tech-
nology and focusing on human tumors,
particularly as this issue may have
important bearings on the development
of therapeutic strategies.
TAM diversity: Both location and
cancer-type matter
Plasticity and diversity are hallmarks of
the mononuclear phagocyte system
[1–4, 29, 30] and there is now evidence
that TAMs in murine tumors consist of
cell populations with substantial differ-
ences [31]. In a transplanted mammary
carcinoma in normoxic and hypoxic
areas TAMs were reported to have an
M1-like and M2-like phenotype, respec-
tively [30]. The microanatomical distri-
butions of cells with different
phenotypes and their relation to mono-
cyte subsets [30] remain to be deter-
mined, however.
A further layer of diversity, namely
the diversity of mechanisms responsible
for TAM generation, occurs at the level
of the tumors and organs involved. Here
are some telling examples. In a model of
human papilloma virus-driven squa-
mous epithelium carcinogenesis, a
remote control pathway involving
CD41 T cells, B cells, antibodies and
Fcg receptors are responsible for the
M2-like phenotype of tumor-promoting
TAMs [32]. In contrast, in a mammary
carcinoma, Th2-derived IL-4 promotes
M2 polarization and metastasis [33]. In
a transplanted mammary carcinoma,
complement was shown to be involved
in myelomonocytic cell recruitment
[34], although the mechanisms
responsible for complement activation
in tumors remain to be defined. It
should be noted that B cells can use
tools other than antibodies to skew
macrophage function and promote
tumor progression, including IL-10 and
lymphotoxin (LT) [35–38], and B
regulatory cells may be well suited for
this [38]. Thus, the mechanisms of
co-opting the function of myelomono-
cytic cells in tumors can differ consid-
erably, although M2-like skewing is a
recurrent common denominator.
Treg cells are characterized by
expression of the Foxp3 transcription
factor. It has recently been observed
that a subset of mouse macrophages
express Foxp3 [39]. Foxp31 macro-
phages appear late in the B16 mela-
noma and, upon adoptive transfer,
promote tumor growth. It will be
important to confirm and extend these
observations to human TAMs.
The diversity of TAMs impacts on the
design of therapeutic strategies given
that, in different tissues and tumors, the
pathways orchestrating TAM develop-
ment and cancer-related inflammation
can differ considerably, and that
myelomonocytic cells come in different
Figure 1. Pathways responsible for macrophage commutation and skewing of macrophage
function in the tumor microenvironment. The picture is a compound of data obtained in
different tumors. Lymphoid cell-derived signals, including Th2 cells, Treg cells and B cells,
influence the TAM phenotype. Moreover, tumor cells and stromal cells are a source of mediators
influencing recruitment, proliferation and functional orientation of TAM.
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flavours in different tumor contexts.
Nonetheless, mononuclear phagocytes
remain as essential common constitu-
ents of cancer-related inflammation and
determining their diversity in different
human cancers is a prerequisite to
translate recent progress in this field
into clinical benefit.
Therapeutic targeting
In most established malignant tumors
TAMs express an M2-like phenotype,
although there are variations and excep-
tions to this common theme [40]. The
TAM phenotype is reversible and these
cells can be re-educated to exert anti-
tumor activity [41–43]. In a recent study
[44], anti-CD40 antibodies with agonist
activity have been shown to have anti-
tumor potential in both murine and
human carcinoma of the pancreas.
Circumstantial evidence suggests that
the anti-tumor activity of CD40 agonist
antibodies is mediated by macrophage
activation. These recent [44] and
previous [4] results, including data from
patients suggest that it is indeed possible
to tip the macrophage balance in an anti-
tumor direction. [10].
Tumor-targeted monoclonal anti-
bodies are part of the cancer ther-
apeutic armamentarium. Macrophages
can mediate antibody-dependent cellu-
lar cytotoxicity and there is evidence
that M2-polarized macrophages phago-
cytose antibody-sensitized lymphoma
cells more efficiently than non-polarized
macrophages [45]. This observation
may explain the apparently divergent
prognostic significance of TAMs in
follicular lymphoma treated with
chemotherapy alone (unfavourable)
and with anti-CD20-containing regi-
mens (favourable) [46]. Thus, the
interaction of macrophages in different
states of activation with antibodies and
more generally with B cells is context-
dependent and can result in promotion
of carcinogenesis (e.g. [33, 35, 38, 47])
or anti-tumor activity [3].
Reducing the numbers or eliminat-
ing TAMs are alternatives to their
re-education. Strategies include inter-
ference with the M-CSF axis [13] or
chemokine expression/function (in
particular CCL2, e.g. [13, 15]), or
depletion of angiogenic monocyte
subsets [48, 49]. Moreover, the influ-
ence of selected chemotherapeutic
agents on the viability and function of
myelomonocytic cells may contribute to
or be a critical component of the agents’
anti-tumor activity [9, 50, 51]. Thus,
the current understanding of TAM
biology opens up different and alter-
native strategies to target these cells,
although the careful definition of the
immunobiology of the context in
different tumors, as noted in the
previous section, may be required for
successful therapeutic exploitation.
Concluding remarks
Macrophages can act as a double-edged
sword in cancer [4, 11]. It has long
been known that appropriately acti-
vated mononuclear phagocytes can
express anti-tumor activity in vitro and
in vivo by direct killing of tumor cells
and/or by eliciting vascular damage
and tissue destruction; however, in the
Darwinian evolution of tumors, TAMs
are co-opted as an integral component
of the neoplastic microenvironment.
Identification of the pathways respon-
sible for the skewing of macrophage
function raises the possibility of macro-
phage-targeted therapies, complemen-
tary to cytoreductive approaches, and of
exploiting TAM as prognostic indicators
[7]; however, a number of open ques-
tions remain as discussed, including the
role and mechanism of recruitment
versus in situ proliferation, and the
diversity both within the tumor micro-
environment and between different
tissues and tumors. A better under-
standing of these issues may help the
better exploitation of the diagnostic and
therapeutic potential of TAMs.
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